Brian Cromer
Family · Peterborough, NHNPI 1457436362
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.6% of the total across 210 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 210 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$862
- Johnson & Johnson$730
- E.r. Squibb & Sons, L.L.C.$543
- LEO Pharma Inc.$446
- Novartis$411
- Lilly USA, LLC$369
- plus $830 from 10 others
What the payments were for
- Food & beverage$3,92594%
- Education$2666%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 42 | $862 |
| Johnson & Johnson | 29 | $730 |
| E.r. Squibb & Sons, L.L.C. | 28 | $543 |
| LEO Pharma Inc. | 26 | $446 |
| Novartis | 24 | $411 |
| Lilly USA, LLC | 18 | $369 |
| Pfizer | 13 | $219 |
| Incyte Corporation | 11 | $201 |
| Sanofi | 5 | $139 |
| Boehringer Ingelheim | 5 | $91 |
| Amgen | 2 | $44 |
| UCB, Inc. | 2 | $42 |
| Arcutis Biotherapeutics, Inc. | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Fresenius Kabi USA, LLC | 1 | $21 |
| Nabriva Therapeutics, PLC | 1 | $16 |
How this compares
$4,191 in reported general payments places this provider in the 95th percentile of 713 family providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 26 | $96,568 |
| Dupixent SyringeDupilumab | 13 | $47,966 |
| Clobetasol Propionate | 38 | $2,107 |
| Triamcinolone Acetonide | 129 | $1,554 |
| Metronidazole | 15 | $916 |
| Fluorouracil | 13 | $640 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 23 | $604 |
| Doxycycline Hyclate | 30 | $435 |
| Ketoconazole | 12 | $267 |
Paid to pharmacies, not to this prescriber.
Other family in Peterborough
- Kayla KokalPeterborough$2K
- Tara Delle ChiaieHampton$548K
- Wendy WrightAmherst$447K
- Richard CareyNashua$51K
- Summer BellDerry$16K
- Laura HudsonDover$14K
- Debra KrisonNorth Hampton$13K
- Michelle WhiteBedford$9K
- Brant OliverConcord$9K
- Cassandra CavanaughDover$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.